Skip to content
2000
image of ZNF146-Mediated HMGB1-NF-κB Signaling Activation as a Therapeutic Target and Prognostic Biomarker in Osteosarcoma

Abstract

Introduction

This study aimed to investigate the role of ZNF146 in osteosarcoma progression and its potential as a therapeutic target and prognostic biomarker, focusing on its interaction with the HMGB1-NF-κB signaling pathway.

Methods

ZNF146 expression was analyzed in osteosarcoma tissues normal tissues using RNA-seq data from the TARGET database and validated in a cohort of 36 patients RT-qPCR, Western blot, and IHC. Functional assays (Transwell, wound healing, colony formation, CCK-8) and molecular analyses (dual-luciferase reporter, ChIP, Western blot) were conducted in MG63 and U2OS cells with ZNF146 modulation. An MG63 xenograft mouse model was used for validation.

Results

ZNF146 was significantly upregulated in osteosarcoma tissues, correlating with poor patient prognosis ( =0.0307). Functionally, ZNF146 overexpression promoted cell proliferation, migration, and invasion, while its knockdown suppressed these effects. Mechanistically, ZNF146 directly binds to the HMGB1 promoter, thereby enhancing HMGB1 expression and activating the NF-κB pathway, which leads to increased cyclin D1 and MMP9 levels. , ZNF146 knockdown resulted in reduced tumor growth and Ki-67/PCNA expression.

Discussion

These findings establish ZNF146 as a key oncogenic driver in osteosarcoma HMGB1-NF-κB signaling. The results align with studies implicating ZNF proteins in tumor progression but highlight a novel mechanism. Limitations include unexplored effects on the tumor microenvironment and the need for validation in larger clinical cohorts.

Conclusion

ZNF146 promotes osteosarcoma progression through HMGB1-mediated NF-κB activation, suggesting its potential as both a prognostic biomarker and a therapeutic target. Inhibition of ZNF146 or HMGB1 may offer novel strategies for osteosarcoma treatment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928387577251118114459
2025-12-24
2026-03-01

  • From This Site

    /content/journals/pra/10.2174/0115748928387577251118114459
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Yu S. Yao X. Advances on immunotherapy for osteosarcoma. Mol. Cancer 2024 23 1 192 10.1186/s12943‑024‑02105‑9 39245737
    [Google Scholar]
  2. Chen C. Xie L. Ren T. Huang Y. Xu J. Guo W. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021 500 1 10 10.1016/j.canlet.2020.12.024 33359211
    [Google Scholar]
  3. Italiano A. Mir O. Mathoulin-Pelissier S. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 21 3 446 455 10.1016/S1470‑2045(19)30825‑3 32078813
    [Google Scholar]
  4. Corre I. Verrecchia F. Crenn V. Redini F. Trichet V. The osteosarcoma microenvironment: A complex but targetable ecosystem. Cells 2020 9 4 976 10.3390/cells9040976 32326444
    [Google Scholar]
  5. Yang C. Tian Y. Zhao F. Bone microenvironment and osteosarcoma metastasis. Int. J. Mol. Sci. 2020 21 19 6985 10.3390/ijms21196985 32977425
    [Google Scholar]
  6. Sun C. Li S. Ding J. Biomaterials‐boosted immunotherapy for osteosarcoma. Adv. Healthc. Mater. 2024 13 23 2400864 10.1002/adhm.202400864 38771618
    [Google Scholar]
  7. Cersosimo F. Lonardi S. Bernardini G. Tumor-associated macrophages in osteosarcoma: From mechanisms to therapy. Int. J. Mol. Sci. 2020 21 15 5207 10.3390/ijms21155207 32717819
    [Google Scholar]
  8. Zheng C. Tang F. Min L. Hornicek F. Duan Z. Tu C. PTEN in osteosarcoma: Recent advances and the therapeutic potential. Biochim. Biophys. Acta Rev. Cancer 2020 1874 2 188405 10.1016/j.bbcan.2020.188405 32827577
    [Google Scholar]
  9. Li Z. Li X. Xu D. An update on the roles of circular RNAs in osteosarcoma. Cell Prolif. 2021 54 1 e12936 10.1111/cpr.12936 33103338
    [Google Scholar]
  10. Wu C.C. Beird H.C. Andrew Livingston J. Immuno-genomic landscape of osteosarcoma. Nat. Commun. 2020 11 1 1008 10.1038/s41467‑020‑14646‑w 32081846
    [Google Scholar]
  11. Zhang Y.F. Wu Y.F. Lan T.J. Chen Y. Su S.H. Codelivery of anticancer drug and photosensitizer by pegylated graphene oxide and cell penetrating peptide enhanced tumor-suppressing effect on osteosarcoma. Front. Mol. Biosci. 2021 7 618896 10.3389/fmolb.2020.618896 33898510
    [Google Scholar]
  12. Olvera-Valencia M. Luna-Maldonado F. Juarez-Reyes J. BUB1 an overexpressed kinase in sarcoma: Finding new target therapy for osteosarcoma, liposarcoma, synovial sarcoma, and leiomyosarcoma. Biomolecules 2025 15 7 1046 10.3390/biom15071046 40723917
    [Google Scholar]
  13. Palmerini E. Sapienza M.R. Pileri S.A. Tumor immune microenvironment-associated prognostic and mifamurtide-response gene signatures for localized osteosarcoma: A correlative study of the ISG/OS2 trial. Clin. Cancer Res. 2025 31 18 3932 3943 10.1158/1078‑0432.CCR‑25‑0649 40711479
    [Google Scholar]
  14. Cui Y. Shi X. Wang Q. COPB2 as a key regulator of cell growth in human osteosarcoma cells: Potential therapeutic target and prognostic indicator. J. Bone Oncol. 2025 53 100702 10.1016/j.jbo.2025.100702 40717795
    [Google Scholar]
  15. Jawhar W. Danieau G. Annett A. Aberrant EZHIP expression drives tumorigenesis in osteosarcoma. Nat. Commun. 2025 16 1 6752 10.1038/s41467‑025‑61558‑8 40695784
    [Google Scholar]
  16. Zoumpoulidou G. Alvarez-Mendoza C. Mancusi C. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nat. Commun. 2021 12 1 7064 10.1038/s41467‑021‑27291‑8 34862364
    [Google Scholar]
  17. Jiang Y. Wang J. Sun M. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. Nat. Commun. 2022 13 1 7207 10.1038/s41467‑022‑34689‑5 36418292
    [Google Scholar]
  18. Shen Y. Zhao S. Wang S. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma. EBioMedicine 2019 40 210 223 10.1016/j.ebiom.2018.12.038 30587459
    [Google Scholar]
  19. Wei Z. Xia K. Zheng D. Gong C. Guo W. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mTOR pathway. Mol. Med. 2023 29 1 133 10.1186/s10020‑023‑00722‑6 37789274
    [Google Scholar]
  20. Wang Q. Yuan X. Li H. Guggulsterone suppresses osteosarcoma progression by inhibiting glycolysis through MAPK signaling pathway. Phytomedicine 2025 144 156949 10.1016/j.phymed.2025.156949 40517691
    [Google Scholar]
  21. Feng L. Xiao G. Chen Y. Cancer-associated fibroblast-like cells promote osteosarcoma metastasis by upregulation of phosphoserine aminotransferase 1 and activation of the mTOR/S6K pathway. Int. J. Biol. Sci. 2025 21 9 4153 4171 10.7150/ijbs.109169 40612679
    [Google Scholar]
  22. Zhou R. Wu H. You H. ESPN activates ZEB1-mediated EMT through the PI3K/AKT/mTOR axis to promote osteosarcoma metastasis. J. Transl. Med. 2025 23 1 527 10.1186/s12967‑025‑06500‑8 40346630
    [Google Scholar]
  23. Ge Q. Yan Z. Tian Q. Xanthohumol regulates mitophagy in osteosarcoma cells via AMPK ‐ ULK1 ‐ FUNDC1 signaling pathway. Phytother. Res. 2025 39 5 2393 2406 10.1002/ptr.8468 40190139
    [Google Scholar]
  24. Su Q. Hou J. Du X. The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma. Oncol. Rev. 2025 19 1615111 10.3389/or.2025.1615111 40599602
    [Google Scholar]
  25. Yu Y. Li K. Peng Y. Tumor microenvironment in osteosarcoma: From cellular mechanism to clinical therapy. Genes Dis. 2025 12 5 101569 10.1016/j.gendis.2025.101569 40600065
    [Google Scholar]
  26. Hsu CY Alkhathami AG Ahmed T Decoding the function of cancer-associated fibroblasts in osteosarcoma: Molecular pathways, therapeutic approaches and prognostic significance. Exp. Cell Res. 2025 450 1 114612 10.1016/j.yexcr.2025.114612 40404112
    [Google Scholar]
  27. Zhra M. Akhund S.A. Mohammad K.S. Advancements in osteosarcoma therapy: Overcoming chemotherapy resistance and exploring novel pharmacological strategies. Pharmaceuticals (Basel) 2025 18 4 520 10.3390/ph18040520 40283955
    [Google Scholar]
  28. Peng X. Feng J. Yang H. Xia P. Pu F. Nrf2: A key regulator in chemoradiotherapy resistance of osteosarcoma. Genes Dis. 2025 12 4 101335 10.1016/j.gendis.2024.101335 40242036
    [Google Scholar]
  29. Sholevar C. Liu N. Mukarrama T. Kim J. Lawrence J. Canter R. Myeloid cells in the immunosuppressive microenvironment as immunotargets in osteosarcoma. ImmunoTargets Ther. 2025 14 247 258 10.2147/ITT.S485672 40125425
    [Google Scholar]
  30. Jiang J. Hedgehog signaling mechanism and role in cancer. Semin. Cancer Biol. 2022 85 107 122 10.1016/j.semcancer.2021.04.003 33836254
    [Google Scholar]
  31. Jen J. Wang Y.C. Zinc finger proteins in cancer progression. J. Biomed. Sci. 2016 23 1 53 10.1186/s12929‑016‑0269‑9 27411336
    [Google Scholar]
  32. Zhao Q. Zhang C. Zhang X. ZNF281 inhibits mitochondrial biogenesis to facilitate metastasis of hepatocellular carcinoma. Cell Death Discov. 2023 9 1 396 10.1038/s41420‑023‑01691‑9 37880213
    [Google Scholar]
  33. Cheng Y. Ni Y.J. Tang L.M. ZNF521 / EBF1 axis regulates AKR1B1 to promote the proliferation, migration, and invasion of gastric cancer cells. Kaohsiung J. Med. Sci. 2023 39 3 244 253 10.1002/kjm2.12624 36397644
    [Google Scholar]
  34. Kamaliyan Z. Clarke T.L. Zinc finger proteins: Guardians of genome stability. Front. Cell Dev. Biol. 2024 12 1448789 10.3389/fcell.2024.1448789 39119040
    [Google Scholar]
  35. Li X. Han M. Zhang H. Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma. Biomark. Res. 2022 10 1 2 10.1186/s40364‑021‑00345‑1 35000617
    [Google Scholar]
  36. Zhu J. Ren S. Yi Y. ZNF146 accelerates lung adenocarcinoma progression through MDM2/p53 and PHGDH/ferroptosis. Cell Biosci. 2025 15 1 94 10.1186/s13578‑025‑01433‑7 40581637
    [Google Scholar]
  37. Jiang F. Huang X. Ling L. Long noncoding RNA ZBED5-AS1 facilitates tumor progression and metastasis in lung adenocarcinoma via ZNF146/ATR/Chk1 axis. Int. J. Mol. Sci. 2023 24 18 13925 10.3390/ijms241813925 37762228
    [Google Scholar]
  38. Zhao R. Song N. Ning X. Chen X. Ma R. ZNF146 regulates cell cycle progression via TFDP1 and DEPDC1B in ovarian cancer cells. Reproduction 2024 168 1 e230484 10.1530/REP‑23‑0484 38614125
    [Google Scholar]
  39. Guo S. Zhang Q. Ma J. PABPN1-C5 axis promotes hepatocellular carcinoma progression via NF-κB activation. Oncogene 2025 44 37 3512 3524 10.1038/s41388‑025‑03501‑1 40721660
    [Google Scholar]
  40. Qu H. Fang Y. Zhang F. CD146 promotes resistance of NSCLC brain metastases to pemetrexed via the NF-κB signaling pathway. Front. Pharmacol. 2025 15 1502165 10.3389/fphar.2024.1502165 39872044
    [Google Scholar]
  41. Wang Y. Peng Y. Hao W. Trillin inhibits MAP3K11/NF-κB/COX-2 signaling pathways through upregulation of miR-145-5p in castration-resistant prostate cancer. iScience 2025 28 2 111505 10.1016/j.isci.2024.111505 39898047
    [Google Scholar]
  42. Pandey P. Lakhanpal S. Mahmood D. An updated review summarizing the anticancer potential of flavonoids via targeting NF-kB pathway. Front. Pharmacol. 2025 15 1513422 10.3389/fphar.2024.1513422 39834817
    [Google Scholar]
  43. Guo Q. Jin Y. Chen X. NF-κB in biology and targeted therapy: New insights and translational implications. Signal Transduct. Target. Ther. 2024 9 1 53 10.1038/s41392‑024‑01757‑9 38433280
    [Google Scholar]
  44. Chen J. Wang T. Li X. DNA of neutrophil extracellular traps promote NF-κB-dependent autoimmunity via cGAS/TLR9 in chronic obstructive pulmonary disease. Signal Transduct. Target. Ther. 2024 9 1 163 10.1038/s41392‑024‑01881‑6 38880789
    [Google Scholar]
  45. Li Y. Zhao B. Peng J. Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers. Drug Resist. Updat. 2024 73 101042 10.1016/j.drup.2023.101042 38219532
    [Google Scholar]
  46. Li R. Shi Y. Zhao S. Shi T. Zhang G. NF-κB signaling and integrin-β1 inhibition attenuates osteosarcoma metastasis via increased cell apoptosis. Int. J. Biol. Macromol. 2019 123 1035 1043 10.1016/j.ijbiomac.2018.11.003 30399378
    [Google Scholar]
  47. Sun T. Song Q. Liu H. CAF-derived exosome-miR-3124-5p promotes malignant biological processes in NSCLC via the TOLLIP/TLR4-MyD88-NF-κB pathway. Oncol. Res. 2024 33 1 133 148 [PMID: 39735680
    [Google Scholar]
  48. Xu Q. Fan G. Shao S. Role of TNFRSF12A in cell proliferation, apoptosis, and proinflammatory cytokine expression by regulating the MAPK and NF-κB pathways in thyroid cancer cells. Cytokine 2025 186 156841 10.1016/j.cyto.2024.156841 39719791
    [Google Scholar]
  49. Chen S. Zhang D. Du Y. Targeting TRAF6/IRF3 axis to inhibit NF-κB-p65 nuclear translocation enhances the chemosensitivity of 5-FU and reverses the proliferation of gastric cancer. Cell Death Dis. 2024 15 12 924 10.1038/s41419‑024‑07290‑5 39706834
    [Google Scholar]
  50. Bahrami A. Khalaji A. Bahri Najafi M. NF-κB pathway and angiogenesis: Insights into colorectal cancer development and therapeutic targets. Eur. J. Med. Res. 2024 29 1 610 10.1186/s40001‑024‑02168‑w 39702532
    [Google Scholar]
  51. Nakai K. Lin H. Yamano S. Wnt activation disturbs cell competition and causes diffuse invasion of transformed cells through NF-κB-MMP21 pathway. Nat. Commun. 2023 14 1 7048 10.1038/s41467‑023‑42774‑6 37923722
    [Google Scholar]
  52. Li X. Jing G. Guo Z. Guo Z. High-mobility group box 1 in acute kidney injury. Front. Pharmacol. 2025 16 1618971 10.3389/fphar.2025.1618971 40727103
    [Google Scholar]
  53. Li J. Zhu C.S. He L. Qiang X. Chen W. Wang H. A two-decade journey in identifying high mobility group box 1 (HMGB1) and procathepsin L (pCTS-L) as potential therapeutic targets for sepsis. Expert Opin. Ther. Targets 2023 27 7 575 591 10.1080/14728222.2023.2239495 37477229
    [Google Scholar]
  54. Sato K. Handa R. Yao J. Release of HMGB1 from human-derived cancer and normal cells by internal targeted radiotherapy with 131I- meta -iodobenzylguanidine. J. Radiat. Res. (Tokyo) 2025 66 4 385 395 10.1093/jrr/rraf034 40583575
    [Google Scholar]
  55. Hubert P. Roncarati P. Demoulin S. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. J. Immunother. Cancer 2021 9 3 e001966 10.1136/jitc‑2020‑001966 33712445
    [Google Scholar]
  56. Wang S. Zhang Y. HMGB1 in inflammation and cancer. J. Hematol. Oncol. 2020 13 1 116 10.1186/s13045‑020‑00950‑x 32831115
    [Google Scholar]
  57. Shen W. Lyu Q. Yi R. HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy. J. Adv. Res. 2024 66 165 180 10.1016/j.jare.2023.12.020 38159843
    [Google Scholar]
  58. Sims G.P. Rowe D.C. Rietdijk S.T. Herbst R. Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 2010 28 1 367 388 10.1146/annurev.immunol.021908.132603 20192808
    [Google Scholar]
  59. Ren W. Zhao L. Sun Y. Wang X. Shi X. HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases. Mol. Med. 2023 29 1 117 10.1186/s10020‑023‑00717‑3 37667233
    [Google Scholar]
  60. Burtscher S. Krieg P. Killinger A. Thin degradable coatings for optimization of osteointegration associated with simultaneous infection prophylaxis. Materials 2019 12 21 3495 10.3390/ma12213495 31731410
    [Google Scholar]
  61. Luo M. Huang M. Yang N. Impairment of rigidity sensing caused by mutant TP53 gain of function in osteosarcoma. Bone Res. 2023 11 1 28 10.1038/s41413‑023‑00265‑w 37246175
    [Google Scholar]
  62. Zhao J. Wen D. Zhang S. Jiang H. Di X. The role of zinc finger proteins in malignant tumors. FASEB J. 2023 37 9 e23157 10.1096/fj.202300801R 37615242
    [Google Scholar]
  63. Ma Y Cong X Zhang Y Yin X Zhu Z Xue Y CircPIP5K1A facilitates gastric cancer progression via miR-376c-3p/ZNF146 axis. Cancer Cell Int. 2020 20 1 81 10.1186/s12935‑020‑1122‑5 32190005
    [Google Scholar]
  64. Zhu S. Chen C.Y. Hao Y. LncRNA KCNQ1OT1 acts as miR-216b-5p sponge to promote colorectal cancer progression via up-regulating ZNF146. J. Mol. Histol. 2021 52 3 479 490 10.1007/s10735‑020‑09942‑0 33394291
    [Google Scholar]
  65. Bao L. Wang M. Fan Q. Hsa_circ_NOTCH3 regulates ZNF146 through sponge adsorption of miR-875-5p to promote tumorigenesis of hepatocellular carcinoma. J. Gastrointest. Oncol. 2021 12 5 2388 2402 10.21037/jgo‑21‑567 34790400
    [Google Scholar]
  66. Shirole N.H. Kesar D. Lee Y. Requirement for cyclin d1 underlies cell-autonomous hif2 dependence in kidney cancer. Cancer Discov. 2025 15 7 1484 1504 10.1158/2159‑8290.CD‑24‑1378 40178040
    [Google Scholar]
  67. Lu K. Zhang M. Qin H. Disruption of cyclin D1 degradation leads to the development of mantle cell lymphoma. Acta Pharm. Sin. B 2024 14 7 2977 2991 10.1016/j.apsb.2024.03.013 39027231
    [Google Scholar]
  68. Arkelius K. Wendt T.S. Andersson H. LOX-1 and MMP-9 inhibition attenuates the detrimental effects of delayed rt-PA therapy and improves outcomes after acute ischemic stroke. Circ. Res. 2024 134 8 954 969 10.1161/CIRCRESAHA.123.323371 38501247
    [Google Scholar]
  69. Wu D. Yang J. Cong J. A disposable VHH-based SPR fiber probe for sensitive and specific detection of MMP-9 in cancer and inflammatory disease. Biosens. Bioelectron. 2025 287 117684 10.1016/j.bios.2025.117684 40499460
    [Google Scholar]
  70. Lei T. Gao Y. Duan Y. Cui C. Zhang L. Si M. Inhibition of zinc finger protein 367 exerts a tumor suppressive role in colorectal cancer by affecting the activation of oncogenic YAP1 signaling. Environ. Toxicol. 2021 36 11 2278 2290 10.1002/tox.23341 34351699
    [Google Scholar]
  71. Zhao S. Cheng L. Ji X. Sun S. Liu Y. Wan Q. A pan-cancer analysis of the prognostic and immunological roles of zinc finger protein 514 in human tumors. Front. Oncol. 2025 15 1592989 10.3389/fonc.2025.1592989 40599863
    [Google Scholar]
  72. Zhai P. Li M. Cheng Y. Exploring the utility of zinc finger protein-related genes in predicting hepatocellular carcinoma prognosis, immune responses, and drug efficacy. Hum. Exp. Toxicol. 2025 44 09603271251340277 10.1177/09603271251340277 40340393
    [Google Scholar]
  73. Munkhjargal B. Kondo K. Soejima S. DNA methylation and mRNA expression of ZNF577 as biomarkers for the detection and prognosis of lung adenocarcinoma. Oncol. Rep. 2024 52 4 131 10.3892/or.2024.8790 39129302
    [Google Scholar]
  74. Hoesel B. Schmid J.A. The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer 2013 12 1 86 10.1186/1476‑4598‑12‑86 23915189
    [Google Scholar]
  75. Bosanac I. Wertz I.E. Pan B. Ubiquitin binding to A20 ZnF4 is required for modulation of NF-κB signaling. Mol. Cell 2010 40 4 548 557 10.1016/j.molcel.2010.10.009 21095585
    [Google Scholar]
  76. Wang T. Wang X. Xu J. Overexpression of the human ZNF300 gene enhances growth and metastasis of cancer cells through activating NF‐k B pathway. J. Cell. Mol. Med. 2012 16 5 1134 1145 10.1111/j.1582‑4934.2011.01388.x 21777376
    [Google Scholar]
  77. Wang W. Guo M. Hu L. The zinc finger protein ZNF268 is overexpressed in human cervical cancer and contributes to tumorigenesis via enhancing NF-κB signaling. J. Biol. Chem. 2012 287 51 42856 42866 10.1074/jbc.M112.399923 23091055
    [Google Scholar]
  78. Yan Z. Zhou Y. Yang Y. Zinc finger protein 384 enhances colorectal cancer metastasis by upregulating MMP2. Oncol. Rep. 2022 47 3 49 10.3892/or.2022.8260 35029289
    [Google Scholar]
  79. Li H. Yang B. Xing K. A preliminary study of the relationship between breast cancer metastasis and loss of heterozygosity by using exome sequencing. Sci. Rep. 2014 4 1 5460 10.1038/srep05460 24964733
    [Google Scholar]
  80. Gualtero D.F. Suarez Castillo A. Biomarkers in saliva for the detection of oral squamous cell carcinoma and their potential use for early diagnosis: A systematic review. Acta Odontol. Scand. 2016 74 3 170 177 10.3109/00016357.2015.1110249 26577643
    [Google Scholar]
  81. Okuno Y. Hattori-Kato M. Tanaka H. Tonooka A. Takeuchi T. Relationship between the reduced expression of zinc finger protein 668 in bladder cancer and its invasiveness. Int. J. Mol. Sci. 2023 24 10 8668 10.3390/ijms24108668 37240013
    [Google Scholar]
  82. He J. Wu M. Xiong L. BTB/POZ zinc finger protein ZBTB16 inhibits breast cancer proliferation and metastasis through upregulating ZBTB28 and antagonizing BCL6/ZBTB27. Clin. Epigenetics 2020 12 1 82 10.1186/s13148‑020‑00867‑9 32517789
    [Google Scholar]
  83. Xiao J. Wei H. Zhou W. Zhang H. Gong H. Wang T. Gene for osteosarcoma subtyping and assessing osteosarcoma prognosis and application thereof. CN Patent 202110663019.4 2021
    [Google Scholar]
  84. Lu Z. Dai K. Osteosarcoma organoid model, construction method and application thereof CN Patent 202210839348 2022
    [Google Scholar]
/content/journals/pra/10.2174/0115748928387577251118114459
Loading
ZNF146-Mediated HMGB1-NF-κB Signaling Activation as a Therapeutic Target and Prognostic Biomarker in Osteosarcoma
Bentham Science Publishers ; https://doi.org/10.2174/0115748928387577251118114459
/content/journals/pra/10.2174/0115748928387577251118114459
/content/journals/pra/10.2174/0115748928387577251118114459
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: ZNF146 ; Osteosarcoma ; NF-κB signaling ; prognosis ; tumor progression ; HMGB1

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test